Adjuvant osimertinib showed clinically meaningful improvement in DFS in the patients with stage IB-IIIA EGFR mutation-positive NSCLC after complete tumor resection and adjuvant chemotherapy (2-year DFS rate was 89% with osimertinib vs 53% with placebo in the overall population) in the ADAURA (NCT02511106) study [29]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.